A 42-year-old woman from Delhi presents with a 6-month history of symmetrical pain and swelling of the wrists, metacarpophalangeal joints, and proximal interphalangeal joints, worse in the morning (lasting 2 hours). She reports fatigue and low-grade fever. On examination, she has warm, tender, swollen joints with reduced grip strength. Laboratory investigations show: ESR 68 mm/h, CRP 12 mg/dL, RF 78 IU/mL (normal <20), anti-CCP antibodies 95 U/mL (normal <20), and hemoglobin 10.2 g/dL. X-ray of hands shows periarticular osteopenia and early marginal erosions at the MCP joints. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis and Rationale **Key Point:** This patient has established seropositive RA (RF and anti-CCP both positive) with evidence of systemic inflammation (elevated ESR/CRP), anemia of chronic disease, and radiographic erosions — all hallmarks of early but active RA requiring prompt DMARD initiation. ## Why DMARD (Methotrexate) is the Correct Answer **High-Yield:** Current EULAR and ACR guidelines (2021) recommend starting a conventional synthetic DMARD (csDMARD) — typically methotrexate — within 3 months of symptom onset in all patients with confirmed RA, regardless of disease activity level, to prevent irreversible joint damage [cite:Harrison 21e Ch 297]. **Clinical Pearl:** The presence of erosions on X-ray indicates that joint destruction is already underway. Delaying DMARD therapy increases the risk of permanent disability. Methotrexate is the anchor drug, with efficacy in 60–70% of patients and a well-established safety profile in RA. ## Window of Opportunity This patient is within the "window of opportunity" (first 12 weeks of symptom onset) when DMARDs are most effective at halting disease progression and preventing erosions. Early, aggressive treatment is now standard of care. **Mnemonic:** **EULAR EARLY** — Early initiation of DMARD therapy in RA leads to better long-term outcomes and lower disability rates. ## Why NSAIDs/Prednisolone Alone Are Insufficient NSAIDs and corticosteroids provide symptomatic relief but do NOT modify disease progression. Prednisolone monotherapy at 20 mg daily would suppress inflammation temporarily but would not prevent erosions and carries long-term toxicity risks (osteoporosis, infection, hyperglycemia). ## Why TNF-α Inhibitors Are Not First-Line Biologic agents (TNF inhibitors, IL-6 inhibitors) are reserved for: - Inadequate response to csDMARD monotherapy after 3 months, OR - High disease activity at baseline with poor prognostic factors (high RF/anti-CCP, early erosions, high ESR/CRP) While this patient has poor prognostic markers, current guidelines still recommend starting with methotrexate first, then escalating to biologics if needed. Direct biologic initiation is considered only in very high-risk patients or in specialized centers. ## Why Joint Aspiration Is Not Indicated Joint aspiration is used to rule out septic arthritis or crystal arthropathies when the diagnosis is unclear. Here, the clinical and serological picture is diagnostic of RA; aspiration would delay necessary DMARD therapy.